An observational study in Heart Failure, sponsored by University Hospital Olomouc. Completed at 1 site in Czechia. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-01-29.
Sponsored by University Hospital Olomouc · Observational
Heart failure is currently not only a major medical but also a socio-economic problem. Its prevalence is estimated at 1-2% of the population with an exponential increase in older age groups. A very important part of the treatment of heart failure is the gradual uptitration of therapy to the maximum tolerated doses. Properly conducted therapy titration requires more frequent patient contact. Thanks to the introduction of telemedicine techniques, the investigators can communicate more effectively with the patient, reach the target doses of heart failure medication faster and subsequently reduce the number of hospitalizations due to worsening of heart failure.
This study investigates effect of advanced telemonitoring of patients with heart failure in home environment.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 25 is below the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →University Hospital Olomouc is the lead sponsor of 40 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with newly diagnosed heart failure with reduced ejection fraction due to non-ischemic cardiomyopathy.
Inclusion Criteria:
Exclusion Criteria:
A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smartwatch, mobile ECG, blood pressure monitor, weight scales, pulse oximetry device.
Evaluation of the effect of step telemonitoring during uptitration of heart failure medication.
Uptitration of therapy guided by data from the medical and other devices (tablet with smartwatch providing data from the pedometer, i.e. number of steps) provided to the patients with heart failure in home environment.
Time frame: 3 month
Evaluation of the effect of ECG telemonitoring during uptitration of heart failure medication.
Uptitration of therapy guided by data from medical and other devices (tablet with mobile ECG) provided to the patients with heart failure in home environment.
Time frame: 3 month
Evaluation of the effect of blood pressure telemonitoring during uptitration of heart failure medication.
Uptitration of therapy guided by data from medical and other devices (tablet and blood pressure monitor recording systolic and diastolic blood pressure) provided to the patients with heart failure in home environment.
Time frame: 3 month
Evaluation of the effect of body weight telemonitoring during uptitration of heart failure medication.
Uptitration of therapy guided by data from medical and other devices (tablet and diagnostic weight scales for monitoring weight in kilograms) provided to the patients with heart failure in home environment.
Time frame: 3 month
Evaluation of the effect of body water telemonitoring during uptitration of heart failure medication.
Uptitration of therapy guided by data from medical and other devices (tablet and diagnostic weight scales for monitoring body water percentage) provided to the patients with heart failure in home environment.
Time frame: 3 month
Evaluation of the effect of blood oxygen saturation telemonitoring during uptitration of heart failure medication.
Uptitration of therapy guided by data from medical and other devices (tablet and pulse oximetry device to monitor blood oxygen saturation in percents) provided to the patients with heart failure in home environment.
Time frame: 3 month
Evaluation of changes of NTproBNP levels at the beginning vs. at the end of the study.
Evaluation of changes of NTproBNPlevels as a marker of effective therapy of heart failure.
Time frame: 3 month
Evaluation of changes in LVEF echocardiographic parameter at the beginning vs. at the end of study.
Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LVEF echocardiographic parameter
Time frame: 3 month
Evaluation of changes in LVEDD echocardiographic parameter at the beginning vs. at the end of study.
Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LVEDD echocardiographic parameter
Time frame: 3 month
Evaluation of changes in LVESD echocardiographic parameter at the beginning vs. at the end of study.
Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LVESD echocardiographic parameter
Time frame: 3 month
Evaluation of changes in LAVi echocardiographic parameter at the beginning vs. at the end of study.
Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in LAVi echocardiographic parameter
Time frame: 3 month
Evaluation of changes in diastolic dysfunction by echocardiography at the beginning vs. at the end of study.
Assessment of the effect of heart failure therapy (left ventricular reverse remodelation) by evaluation of changes in diastolic dysfunction.
Time frame: 3 month
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Olomouc